Publications

  • Report on the blood product area in 2009

    | 17 August 2010 |

    In 2009, 358.000 blood collections were made in Denmark. This is approximately 4.000 collections more than the previous year. Moreover, approximately 332.000 units of red blood cells (erythrocytes) were used in connection with blood transfusions in 2009.

  • Product defects and withdrawal of medicinal products in 2009

    | 15 June 2010 |

    In 2009, 186 reports of medicinal product defects were registered, which is slightly more than in 2008. Compared to 2008, the reporting sources and types of defects have shifted, and reports from the Danish Medicines Agency's own control system accounted for a larger share in 2009 compared to 2008.

  • Annual report 2009 of the Danish Medicines Agency's laboratory control activities

    | 14 June 2010 |

    The medical authorities in Europe cooperate in a network called the Official Medicines Control Laboratories (OMCL). The Danish Medicines Agency has published an annual report for 2009 that d

  • Report on compliance with rules on good manufacturing practice by manufacturers of active pharmaceutical ingredients

    | 20 May 2010 |

    Since December 2005, it has been a requirement that any active pharmaceutical ingredients (API) used in medicines with a marketing authorisation in Denmark must be manufactured in compliance with the

  • Annual report of the Reimbursement Committee 2009

    | 23 April 2010 |

    Members appointed by the Danish Minister for the Interior and Health 17 meetings in 2009 21 applications for general reimbursement Grounds 1632 applications for individual reimbursement Annual

  • Number of applications for individual reimbursement of medicinal products in 2009

    | 31 March 2010 |

    Reimbursement for the chronically ill Increased reimbursement Single reimbursement Medicinal product groups generating the highest number of single reimbursement applications Electronic ap

  • Danish Medicines Agency’s annual pharmacovigilance report 2009

    | 29 March 2010 |

    The annual report offers an insight into the pharmacovigilance work performed by the Danish Medicines Agency in 2009.

  • Annual report on human tissues and cells 2008

    | 05 March 2010 |

    The Danish Medicines Agency's annual report on human tissues and cells has been prepared pursuant to the Danish Tissue Act and is based on reports submitted by the tissue establisments and gynaecology clinics in Denmark in the period January to December 2008

  • Report on the blood product area in 2008

    | 02 September 2009 |

    The blood product report is published every year based on figures from the Danish blood centres and the Blood-donors in Denmark.

  • Annual report on the inspection of retail sale of OTC medicines 2008-2009

    | 23 July 2009 |

    In 2008, the Danish Medicines Agency intensified its efforts on removing expired over-the-counter medicine from retail distribution.

  • Performance contract 2009

    | 03 July 2009 |

    The Danish Medicines Agency and the Ministry of Health and Prevention have agreed upon a performance contract, which is valid for 2009. The contract, which is in Danish only, focuses on external targets that cover the Danish Medicines Agency's tasks to the greatest extent possible.

  • Number of applications for individual reimbursement of medicinal products in 2008

    | 28 April 2009 |

    Reimbursement for the chronically ill Increased reimbursement Single reimbursement Medicinal product groups subject to the most single reimbursement applications In

  • Danish Medicines Agency annual accounts 2008

    | 17 April 2009 |

    In 2008, the Danish Medicines Agency achieved a target performance of 91.9 per cent in respect of the targets set out in the performance contract with the Danish Ministry of Health and Prevention, corresponding to a fulfillment of four in every five sub-requirements. Overall, we find that we delivered good technical results in 2008.

  • Product defects and withdrawal of medicinal products in 2008

    | 16 April 2009 |

    In 2008, 177 reports of medicinal product defects were registered, which is less than in 2007. 23 % of these reports led to products being withdrawn from the market, which is also less than in the preceding years. Most of the withdrawals effected in 2008 were occasioned by reports made by the companies.

  • Performance contract 2008

    | 19 December 2008 |

  • Report on the blood product area in 2007

    | 13 October 2008 |

    The blood product report is published every year based on figures from the Danish blood centres and the Blood-donors in Denmark.

  • Survey of pharmaceutical companies' satisfaction with the Danish Medicines Agency

    | 19 September 2008 |

    The research company Capacent Epinion has asked pharmaceutical companies to indicate their level of satisfaction with the Danish Medicines Agency. A total of 40 companies participated in the survey, which was carried out in May to June 2008.

  • Danish Medicines Agency annual report 2007

    | 10 September 2008 |

    The annual report 2007 takes you through important activities within the Danish Medicines Agency in 2007. On a number of theme pages, we also tell about projects that strengthen our cooperation with the business sector, our relations to consumers and our involvement in European development.

  • Product defects and withdrawal of medicinal products in 2007

    | 19 May 2008 |

    In 2007, 202 reports about medicinal product defects were registered, which is basically on level with 2006. 28 % of these reports resulted in a withdrawal from the Danish market, which is exactly the same proportion as the year before.

  • Danish Medicines Agency annual accounts 2007

    | 22 April 2008 |

    In 2007, the Danish Medicines Agency achieved a target performance of 93.9 per cent in respect of the targets set out in the performance contract with the Danish Ministry of Health and Prevention, corresponding to a fulfillment of three in every four sub-requirements. Overall, we assess that we delivered good technical results in 2007, among other things, based on the fact that the most strategically important performance requirements were fulfilled.

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.